ZL-1310

Phase 3Small molecule

ZZai Lab (Shanghai) Co., Ltd.

ZL-1310 is one of 71 small molecule programs targeting Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung CancerRecruiting

Solid TumorRecruiting

Small Cell Lung CancerPhase 3

Recruiting

Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

31 2

Camptosar

Pfizer

Phase 3

26 3

Zepzelca

Jazz Pharmaceuticals

Phase 3

10 4

Lenvima

Eisai

Phase 3

5 5

Lazcluze

Johnson & Johnson

Phase 3

1 6

Rybrevant

Johnson & Johnson

Phase 3

1 7

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

7 8

Ifex

BBaxter Healthcare Corporation

Phase 3

5 9

MEDI4736

AstraZeneca

Phase 3

2 10

Navmi

SSummit Therapeutics

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Small Cell Lung Cancer

NCT06179069

Q2 2028

PreclinicalRecruiting

Solid Tumor

NCT06885281

Q4 2028

Phase 3Recruiting

Small Cell Lung Cancer

NCT07218146

Clinical

Trials by Indication[1]

Small Cell Lung Cancer2 trials

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 1·NCT06179069·112 enrolled

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Phase 3·NCT07218146·480 enrolled

Solid Tumor1 trial

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Recruiting·ZZai Lab (Shanghai) Co., Ltd.·Preclinical·NCT06885281·166 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ZL-1310. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZL-1310 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZL-1310. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zai Lab (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: ZZai Lab (Shanghai) Co., Ltd.

ZL-1310

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Small Cell Lung Cancer2 trials

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News